The Lancet
出版商:Elsevier · ISSN:0140-6736, 1474-547X, 0099-5355 · 国家/地区:NL · 类型:journal · 创刊:1823 · 官网:https://www.sciencedirect.com/journal/the-lancet
研究主题:Human auditory perception and evaluation · Diverse Scientific and Economic Studies · Earthquake and Disaster Impact Studies · Primary Care and Health Outcomes · Medical History and Innovations
核心指标
- 影响因子(JCR 2025):109.000
- JCR 分区:Q1(MEDICINE, GENERAL & INTERNAL)
- 中科院分区(2025):医学 1区(Top);小类:MEDICINE, GENERAL & INTERNAL 医学:内科 1区
- 新锐分区(2026):医学 1区
- SJR:14.821(Q1)
- h-index:1208
- i10 指数:70652
- 近两年篇均被引:19.93
- 载文量 475870 · 总被引 10418641
逐年趋势
- 近年影响因子:2021 203 → 2022 169 → 2023 98.4 → 2024 88.5 → 2025 109
- 近年 SJR:2021 15.7(Q1) → 2022 14.6(Q1) → 2023 12.1(Q1) → 2024 12.1(Q1) → 2025 14.8(Q1)
投稿参考
- 审稿周期:首次审稿意见平均约 1.4 个月
- 投稿人评价:3.0 分(72 条评价)
- 版面费(APC)约 $7890 USD(以期刊官网为准)
- 提供 LaTeX 投稿模板(elsarticle.cls)
同学科期刊推荐
- CA-A CANCER JOURNAL FOR CLINICIANS — IF 685.2 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Clinical Oncology — IF 94.6 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Drug Discovery — IF 91.2 · JCR Q1 · 中科院1区(Top)
- Kidney International Supplements — IF 89.6 · JCR Q1 · 中科院2区
- New England Journal of Medicine — IF 84.5 · JCR Q1 · 中科院1区(Top)
- Signal Transduction and Targeted Therapy — IF 81.2 · JCR Q1 · 中科院1区(Top)
- Annals of Oncology — IF 80.4 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Disease Primers — IF 79.8 · JCR Q1 · 中科院1区(Top)
常见问题
《The Lancet》的影响因子是多少?
根据 JCR 2025 年数据,《The Lancet》的最新影响因子(IF)为 109.000。
《The Lancet》是几区期刊?
《The Lancet》中科院分区(2025年版)为医学1区(Top 期刊),JCR 分区为 Q1。
《The Lancet》的审稿周期多久?
根据投稿经验数据,《The Lancet》首次审稿意见平均约 1.4 个月返回,实际周期因稿件而异。
《The Lancet》的版面费(APC)是多少?
根据 OpenAlex 收录的价目,《The Lancet》的文章处理费(APC)约为 $7890 美元。实际费用与豁免政策请以期刊官网为准。
本刊近期代表论文
- Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials (2026 · 被引 28)
- Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial (2026 · 被引 20)
- Updated trends in the global prevalence and burden of mental disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 (2026 · 被引 17)
- Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18–65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network (2026 · 被引 7)
- Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials (2026 · 被引 5)
- Progress towards the WHO Global Initiative for Childhood Cancer target of 60% 5-year survival for all childhood cancers combined, 1990–2019 (CONCORD-4): a Cancer Survival Index derived for 68 countries by analysis of individual records for 613 021 children from 307 population-based cancer registries (2026 · 被引 4)